Matthew N Alder1, Amy M Opoka, Patrick Lahni, David A Hildeman, Hector R Wong. 1. 1Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Children's Hospital Research Foundation, Cincinnati, OH.2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.3Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Children's Hospital Research Foundation, Cincinnati, OH.
Abstract
OBJECTIVES: Heterogeneity in sepsis-related pathobiology presents a significant challenge. Resolving this heterogeneity presents an opportunity to understand pathobiology and improve patient care. Olfactomedin-4 is a neutrophil subset marker and may contribute to sepsis heterogeneity. Our objective was to evaluate the expression of olfactomedin-4 and characterize neutrophil heterogeneity in children with septic shock. DESIGN: Single-center, prospective cohort, as well as secondary analysis of existing transcriptomic and proteomic databases. SETTING: Tertiary care PICU. PATIENTS: Patients from 5 days to 18 years old with septic shock were enrolled. Data collected included the expression of olfactomedin-4 messenger RNA, serum protein concentrations, and percentage of neutrophils that express olfactomedin-4. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Secondary analysis of existing transcriptomic data demonstrated that olfactomedin-4 is the most highly expressed gene in nonsurvivors of pediatric septic shock, compared with survivors. Secondary analysis of an existing proteomic database corroborated these observations. In a prospectively enrolled cohort, we quantified the percentage of olfactomedin-4+ neutrophils in patients with septic shock. Patients with a complicated course, defined as greater than or equal to two organ failures at day 7 of septic shock or 28-day mortality, had a higher percentage of olfactomedin-4+ neutrophils, compared with those without a complicated course. By logistic regression, the percentage of olfactomedin-4+ neutrophils was independently associated with increased risk of a complicated course (odds ratio, 1.09; 95% CI, 1.01-1.17; p = 0.024). CONCLUSIONS: Olfactomedin-4 identifies a subpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfactomedin-4+ neutrophils are at higher risk for greater organ failure burden and death. Olfactomedin-4 might serve as a marker of a pathogenic neutrophil subset in patients with septic shock.
OBJECTIVES: Heterogeneity in sepsis-related pathobiology presents a significant challenge. Resolving this heterogeneity presents an opportunity to understand pathobiology and improve patient care. Olfactomedin-4 is a neutrophil subset marker and may contribute to sepsis heterogeneity. Our objective was to evaluate the expression of olfactomedin-4 and characterize neutrophil heterogeneity in children with septic shock. DESIGN: Single-center, prospective cohort, as well as secondary analysis of existing transcriptomic and proteomic databases. SETTING: Tertiary care PICU. PATIENTS: Patients from 5 days to 18 years old with septic shock were enrolled. Data collected included the expression of olfactomedin-4 messenger RNA, serum protein concentrations, and percentage of neutrophils that express olfactomedin-4. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Secondary analysis of existing transcriptomic data demonstrated that olfactomedin-4 is the most highly expressed gene in nonsurvivors of pediatric septic shock, compared with survivors. Secondary analysis of an existing proteomic database corroborated these observations. In a prospectively enrolled cohort, we quantified the percentage of olfactomedin-4+ neutrophils in patients with septic shock. Patients with a complicated course, defined as greater than or equal to two organ failures at day 7 of septic shock or 28-day mortality, had a higher percentage of olfactomedin-4+ neutrophils, compared with those without a complicated course. By logistic regression, the percentage of olfactomedin-4+ neutrophils was independently associated with increased risk of a complicated course (odds ratio, 1.09; 95% CI, 1.01-1.17; p = 0.024). CONCLUSIONS:Olfactomedin-4 identifies a subpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfactomedin-4+ neutrophils are at higher risk for greater organ failure burden and death. Olfactomedin-4 might serve as a marker of a pathogenic neutrophil subset in patients with septic shock.
Authors: Hector R Wong; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Scott L Weiss; Thomas P Shanley; Michael T Bigham; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Jerry J Zimmerman Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Stine N Clemmensen; Christina T Bohr; Sara Rørvig; Andreas Glenthøj; Helena Mora-Jensen; Elisabeth P Cramer; Lars C Jacobsen; Maria T Larsen; Jack B Cowland; Julia T Tanassi; Niels H H Heegaard; Jonathan D Wren; Asli N Silahtaroglu; Niels Borregaard Journal: J Leukoc Biol Date: 2011-12-20 Impact factor: 4.962
Authors: Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie Fitzgerald; Paul A Checchia; Keith Meyer; Thomas P Shanley; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Shekhar S Raj; Shira Gertz; Emily Dawson; Kelli Howard; Kelli Harmon; Patrick Lahni; Erin Frank; Kimberly W Hart; Christopher J Lindsell Journal: Crit Care Med Date: 2015-08 Impact factor: 7.598
Authors: Janesh Pillay; Bart P Ramakers; Vera M Kamp; Adele Lo Tam Loi; Siu W Lam; Falco Hietbrink; Luke P Leenen; Anton T Tool; Peter Pickkers; Leo Koenderman Journal: J Leukoc Biol Date: 2010-04-16 Impact factor: 4.962
Authors: Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie Fitzgerald; Paul A Checchia; Keith Meyer; Thomas P Shanley; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Raj S Shekhar; Shira Gertz; Emily Dawson; Kelli Howard; Kelli Harmon; Eileen Beckman; Erin Frank; Christopher J Lindsell Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: N Hu; J Westra; M G Huitema; M Bijl; E Brouwer; C A Stegeman; P Heeringa; P C Limburg; C G M Kallenberg Journal: Arthritis Rheum Date: 2009-05
Authors: Kamal Abulebda; Natalie Z Cvijanovich; Neal J Thomas; Geoffrey L Allen; Nick Anas; Michael T Bigham; Mark Hall; Robert J Freishtat; Anita Sen; Keith Meyer; Paul A Checchia; Thomas P Shanley; Jeffrey Nowak; Michael Quasney; Scott L Weiss; Arun Chopra; Sharon Banschbach; Eileen Beckman; Christopher J Lindsell; Hector R Wong Journal: Crit Care Med Date: 2014-02 Impact factor: 7.598
Authors: Philipp Kruger; Mona Saffarzadeh; Alexander N R Weber; Nikolaus Rieber; Markus Radsak; Horst von Bernuth; Charaf Benarafa; Dirk Roos; Julia Skokowa; Dominik Hartl Journal: PLoS Pathog Date: 2015-03-12 Impact factor: 6.823
Authors: Julie E Stark; Amy M Opoka; Jaya Mallela; Prasad Devarajan; Qing Ma; Nick C Levinsky; Keith F Stringer; Hector R Wong; Matthew N Alder Journal: Am J Physiol Renal Physiol Date: 2020-02-18
Authors: Kirsten N Kangelaris; Regina Clemens; Xiaohui Fang; Alejandra Jauregui; Tom Liu; Kathryn Vessel; Thomas Deiss; Pratik Sinha; Aleksandra Leligdowicz; Kathleen D Liu; Hanjing Zhuo; Matthew N Alder; Hector R Wong; Carolyn S Calfee; Clifford Lowell; Michael A Matthay Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-12-23 Impact factor: 5.464
Authors: Al-Faraaz Kassam; Nick C Levinsky; Jaya P Mallela; Kira Angel; Amy Opoka; Patrick Lahni; Rashmi D Sahay; Lin Fei; Vanessa Nomellini; Hector R Wong; Matthew N Alder Journal: Am J Respir Cell Mol Biol Date: 2021-02 Impact factor: 6.914
Authors: Nick C Levinsky; Jaya Mallela; Amy M Opoka; Kelli Harmon; Hannah V Lewis; Basilia Zingarelli; Hector R Wong; Matthew N Alder Journal: FASEB J Date: 2019-10-08 Impact factor: 5.834